Article Text

Download PDFPDF
Randomised controlled trial
Coronary artery bypass surgery continues to remain the treatment of choice for multivessel coronary artery disease even in the era of new-generation drug-eluting stents
  1. Friedrich W Mohr,
  2. Piroze M Davierwala
  1. Department of Cardiac Surgery, Herzzentrum, Leipzig, Germany
  1. Correspondence to : Dr Friedrich W Mohr, Department of Cardiac Surgery, Herzzentrum, Struempellstrasse 39, Leipzig 04289, Germany; mohrf{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Multivessel coronary artery disease (MVCAD) may be found in patients subjected to coronary angiography. It is treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). The expanded use of PCI, following development of drug-eluting stents (DES), necessitated comparison of its outcomes with CABG (gold standard therapy). The SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) trial favoured CABG with regard to occurrence of cardiac death, myocardial infarction (MI), repeat revascularisation, and major cardiac and cerebrovascular events.1 New-generation DES and new antiproliferative agents have better efficacy and safety than …

View Full Text


  • Competing interests FWM was one of the principal investigators for the SYNTAX trial.

  • Provenance and peer review Commissioned; internally peer reviewed.